Cargando…

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1. The VEXAS syndrome often overlaps with...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huijun, Zhang, Wenjun, Cai, Wenyu, Liu, Jinqin, Wang, Huijun, Qin, Tiejun, Xu, Zefeng, Li, Bing, Qu, Shiqiang, Pan, Lijuan, Huang, Gang, Gale, Robert Peter, Xiao, Zhijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976711/
https://www.ncbi.nlm.nih.gov/pubmed/33741056
http://dx.doi.org/10.1186/s40164-021-00217-2
Descripción
Sumario:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1. The VEXAS syndrome often overlaps with myelodysplastic syndromes (MDS) with autoimmune disorders (AD). By screening the UBA1 gene sequences derived from MDS patients with AD from our center, we identified one patient with a p.Met41Leu missense mutation in UBA1, who should have been diagnosed as MDS comorbid with VEXAS syndrome. This patient respond poorly to immune suppressive drugs. Patients with MDS and AD who have characteristic vacuoles in myeloid and erythroid precursor cells should be screened for UBA1 mutation, these patients are likely to have VEXAS syndrome and unlikely to improve with immunosuppressive drugs and should be considered for other alternative therapies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-021-00217-2.